Chapter 9 Antithrombotic Therapy for Secondary Prevention of Ischemic Stroke

Blue Books of Practical Neurology

Volumn 29, Issue C, 2004, Pages 175-196

  Fayad, Pierre ^a   Singh, Sanjay P ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

EID: 77957242164     PISSN: 18773419     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S1877-3419(09)70084-4     Document Type: Article

References (67)

1. Petty G.W., Brown Jr. R.D., Whisnant J.P., et al. Survival and recurrence after first cerebral infarction: a population-based study in Rochester, Minnesota, 1975 through 1989. Neurology 50 (1998) 208-216
2. Sacco R.L., Shi T., Zamanillo M.C., and Kargman D.E. Predictors of mortality and recurrence after hospitalized cerebral infarction in an urban community: the Northern Manhattan Stroke Study. Neurology 44 (1994) 626-634
3. Hier D.B., Foulkes M.A., Swiontoniowski M., et al. Stroke recurrence within 2 years after ischemic infarction. Stroke 22 (1991) 155-161
4. Libby P., and Aikawa M. Stabilization of atherosclerotic plaques: new mechanisms and clinical targets. Nat Med 8 (2002) 1257-1262
5. Rosenberg R.D., and Aird W.C. Vascular-bed-specific hemostasis and hypercoagulable states. N Engl J Med 340 (1999) 1555-1564
6. Farb A., Burke A.P., Tang A.L., et al. Coronary plaque erosion without rupture into a lipid core. A frequent cause of coronary thrombosis in sudden coronary death. Circulation 93 (1996) 1354-1363
7. Hirsh J., and Weitz J.I. New antithrombotic agents. Lancet 353 (1999) 1431-1436
8. Hirsh J., Dalen J., Anderson D.R., et al. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest 119 1 Suppl (2001) 8S-21S
9. Patients with nonvalvular atrial fibrillation at low risk of stroke during treatment with aspirin: Stroke Prevention in Atrial Fibrillation III Study. The SPAF III Writing Committee for the Stroke Prevention in Atrial Fibrillation Investigators. JAMA 279 (1998) 1273-1277
10. A randomized trial of anticoagulants versus aspirin after cerebral ischemia of presumed arterial origin. The Stroke Prevention in Reversible Ischemia Trial (SPIRIT) Study Group. Ann Neurol 42 (1997) 857-865
11. Mohr J.P., Thompson J.L., Lazar R.M., et al. A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke. N Engl J Med 345 (2001) 1444-1451
12. Homma S., Sacco R.L., Di Tullio M.R., et al. Effect of medical treatment in stroke patients with patent foramen ovale: patent foramen ovale in Cryptogenic Stroke Study. Circulation 105 (2002) 2625-2631
13. Petersen P., Grind M., and Adler J. Ximelagatran versus warfarin for stroke prevention in patients with nonvalvular atrial fibrillation. SPORTIF II: a dose-guiding, tolerability, and safety study. J Am Coll Cardiol 41 (2003) 1445-1451
14. Chew D.P., Bhatt D.L., Sapp S., et al. Increased mortality with oral platelet glycoprotein IIb/IIIa antagonists: a meta-analysis of phase III multicenter randomized trials. Circulation 103 (2001) 201-206
15. Bhatt D.L., and Topol E.J. Scientific and therapeutic advances in antiplatelet therapy. Nat Rev Drug Discov 2 (2003) 15-28
16. Vane J.R., Bakhle Y.S., and Botting R.M. Cyclooxygenases 1 and 2. Annu Rev Pharmacol Toxicol 38 (1998) 97-120
17. Burch J.W., Stanford N., and Majerus P.W. Inhibition of platelet prostaglandin synthetase by oral aspirin. J Clin Invest 61 (1978) 314-319
18. Patrono C., Coller B., Dalen J.E., et al. Platelet-active drugs: the relationships among dose, effectiveness, and side effects. Chest 119 l Suppl (2001) 39S-63S
19. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 324 (2002) 71-86
20. Hart R.G., Halperin J.L., McBride R., et al. Aspirin for the primary prevention of stroke and other major vascular events: meta-analysis and hypotheses. Arch Neurol 57 (2000) 326-332
21. Fields W.S., Lemak N.A., Frankowski R.F., et al. Controlled trial of aspirin in cerebral ischemia. Stroke 8 (1977) 301-314
22. A randomized trial of aspirin and sulfinpyrazone in threatened stroke. The Canadian Cooperative Study Group. N Engl J Med 299 (1978) 53-59
23. Reuther R., and Dorndorf W. Aspirin in Patients with Cerebral Ischemia and Normal Angiograms or Non-surgical Lesions: The Results of a Double-Blind Trial. In: Breddin K., Dorndorf W., Loew D., et al. (Eds). Acetylsalicylic Acid in Cerebral Ischemia and Coronary Heart Disease: IV Colfarit-Symposion, Berlin, 30.9.-1.10., 1977 (1978), Schattauer Verlag, Stuttgart, Germany 97-106
24. Guiraud-Chaumeil B., Rascol A., David J., et al. Prévention des récidives des accidents vasculaires cerebraux ischémiques par les anti-agrégants plaquettaires: résultats d'un essai thérapeutique contrôlé de 3 ans. Rev Neurol (Paris) 138 (1982) 367-385
25. Sorensen P.S., Pedersen H., Marquardsen J., et al. Acetylsalicylic acid in the prevention of stroke in patients with reversible cerebral ischemic attacks. A Danish cooperative study. Stroke 14 (1983) 15-22
26. Bousser M.G., Eschwege E., Haguenau M., et al. "AICLA" controlled trial of aspirin and dipyridamole in the secondary prevention of athero-thrombotic cerebral ischemia. Stroke 14 (1983) 5-14
27. High-dose acetylsalicylic acid after cerebral infarction. A Swedish Cooperative Study. Stroke 18 (1987) 325-334
28. Boysen G., Sorensen P.S., Juhler M., et al. Danish very-low-dose aspirin after carotid endarterectomy trial. Stroke 19 (1988) 1211-1215
29. Farrell B., Godwin J., Richards S., et al. The United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: final results. J Neurol Neurosurg Psychiatry 54 (1991) 1044-1054
30. Swedish Aspirin Low-Dose Trial (SALT) of 75 mg aspirin as secondary prophylaxis after cerebrovascular ischaemic events. The SALT Collaborative Group. Lancet 338 (1991) 1345-1349
31. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. EAFT (European Atrial Fibrillation Trial) Study Group. Lancet 342 (1993) 1255-1262
32. Diener H.C., Cunha L., Forbes C., et al. European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci 143 (1996) 1-13
33. Barnett H.J., Eliasziw M., and Meldrum H.E. Drugs and surgery in the prevention of ischemic stroke. N Engl J Med 332 (1995) 238-248
34. Algra A., and van Gijn J. Aspirin at any dose above 30 mg offers only modest protection after cerebral ischaemia. J Neurol Neurosurg Psychiatry 60 (1996) 197-199
35. Johnson E.S., Lanes S.F., Wentworth III C.E., et al. A metaregression analysis of the dose-response effect of aspirin on stroke. Arch Intern Med 159 (1999) 1248-1253
36. Tijssen J.G. Low-dose and high-dose acetylsalicylic acid, with and without dipyridamole: a review of clinical trial results. Neurology 51 3 Suppl 3 (1998) S15-S16
37. The Dutch TIA trial: protective effects of low-dose aspirin and atenolol in patients with transient ischemic attacks or nondisabling stroke. The Dutch TIA Study Group. Stroke 19 (1988) 512-517
38. Taylor D.W., Barnett H.J., Haynes R.B., et al. Low-dose and high-dose acetylsalicylic acid for patients undergoing carotid endarterectomy: a randomised controlled trial. ASA and Carotid Endarterectomy (ACE) Trial Collaborators. Lancet 353 (1999) 2179-2184
39. Barnett H.J., Taylor D.W., Eliasziw M., et al. Benefit of carotid endarterectomy in patients with symptomatic moderate or severe stenosis. North American Symptomatic Carotid Endarterectomy Trial Collaborators. N Engl J Med 339 (1998) 1415-1425
40. Albers G.W., Amarenco P., Easton J.D., et al. Antithrombotic and thrombolytic therapy for ischemic stroke. Chest 119 l Suppl (2001) 300S-320S
41. Bornstein N.M., Karepov V.G., Aronovich B.D., et al. Failure of aspirin treatment after stroke. Stroke 25 (1994) 275-277
42. Helgason C.M., Bolin K.M., Hoff J.A., et al. Development of aspirin resistance in persons with previous ischemic stroke. Stroke 25 (1994) 2331-2336
43. Gum P.A., Kottke-Marchant K., Welsh P.A., et al. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol 41 (2003) 961-965
44. He J., Whelton P.K., Vu B., and Klag M.J. Aspirin and risk of hemorrhagic stroke: a meta-analysis of randomized controlled trials. JAMA 280 (1998) 1930-1935
45. Kronmal R.A., Hart R.G., Manolio T.A., et al. Aspirin use and incident stroke in the cardiovascular health study. CHS Collaborative Research Group. Stroke 29 (1998) 887-894
46. Boysen G. Bleeding complications in secondary stroke prevention by antiplatelet therapy: a benefit-risk analysis. J Intern Med 246 (1999) 239-245
47. McNeely W., and Goa K.L. Triflusal. Drugs 55 (1998) 823-833 discussion 834-825.
48. Matias-Guiu J., Ferro J.M., Alvarez-Sabin J., et al. Comparison of triflusal and aspirin for prevention of vascular events in patients after cerebral infarction: the TACIP Study: a randomized, double-blind, multicenter trial. Stroke 34 (2003) 840-848
49. Gent M., Blakely J.A., Easton J.D., et al. The Canadian American Ticlopidine Study (CATS) in throm-boembolic stroke. Lancet l (1989) 1215-1220
50. Hass W.K., Easton J.D., Adams Jr. H.P., et al. A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. Ticlopidine Aspirin Stroke Study Group. N Engl J Med 321 (1989) 501-507
51. Weisberg L.A. The efficacy and safety of ticlopidine and aspirin in non-whites: analysis of a patient subgroup from the Ticlopidine Aspirin Stroke Study. Neurology 43 (1993) 27-31
52. Gorelick P.B., Richardson D., Kelly M., et al. Aspirin and ticlopidine for prevention of recurrent stroke in black patients: a randomized trial. JAMA 289 (2003) 2947-2957
53. Bennett C.L., Davidson C.J., Raisch D.W., et al. Thrombotic thrombocytopenic purpura associated with ticlopidine in the setting of coronary artery stents and stroke prevention. Arch Intern Med 159 (1999) 2524-2528
54. Spiera R.F., Berman R.S., Werner A.J., et al. Ticlopidine-induced lupus: a report of 4 cases. Arch Intern Med 162 (2002) 2240-2243
55. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet 348 (1996) 1329-1339
56. Bennett C.L., Connors J.M., Carwile J.M., et al. Thrombotic thrombocytopenic purpura associated with clopidogrel. N Engl J Med 342 (2000) 1773-1777
57. Lau W.C., Waskell L.A., Watkins P.B., et al. Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug-drug interaction. Circulation 107 (2003) 32-37
58. Yusuf S., Zhao F., Mehta S.R., et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 345 (2001) 494-502
59. Steinhubl S.R., Berger P.B., Mann III J.T., et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 288 (2002) 2411-2420
60. Albers G.W., and Amarenco P. Combination therapy with clopidogrel and aspirin: can the CURE results be extrapolated to cerebrovascular patients?. Stroke 32 (2001) 2948-2949
61. Bhatt D.L., Bertrand M.E., Berger P.B., et al. Meta-analysis of randomized and registry comparisons of ticlopidine with clopidogrel after stenting. J Am Coll Cardiol 39 (2002) 9-14
62. Mueller C., Roskamm H., Neumann F.J., et al. A randomized comparison of clopidogrel and aspirin versus ticlopidine and aspirin after the placement of coronary artery stents. J Am Coll Cardiol 41 (2003) 969-973
63. Hacke W. From CURE to MATCH: ADP receptor antagonists as the treatment of choice for high-risk atherothrombotic patients. Cerebrovasc Dis 13 Suppl l (2002) 22-26
64. Wilterdink J.L., and Easton J.D. Dipyridamole plus aspirin in cerebrovascular disease. Arch Neurol 56 (1999) 1087-1092
65. Persantine aspirin trial in cerebral ischemia-Part III: risk factors for stroke. The American-Canadian Co-Operative Study Group. Stroke 17 (1986) 12-18
66. European Stroke Prevention Study. ESPS Group. Stroke 21 (1990) 1122-1130
67. Muller T.H. Inhibition of thrombus formation by low-dose acetylsalicylic acid, dipyridamole, and their combination in a model of platelet-vessel wall interaction. Neurology 57 5 Suppl 2 (2001) S8-S11